- Guselkumab is associated with better long-term efficacy compared with ustekinumab for patients with moderate to severe psoriasis, according to an indirect comparison using pooled analysis of individual patient data from the VOYAGE 1/2 and NAVIAGATE trials.
Why this matters
- There have been no head-to-head comparisons of guselkumab and ustekinumab, necessitating this type of indirect comparison.
- Guselkumab was associated with a higher probability of achieving ≥90% reduction in the Psoriasis Area and Severity Index (PASI 90) compared with ustekinumab at week 40 (74.2% vs 54.5% [OR, 2.40; 95% CI, 1.89-3.13]).
- At 40 weeks, guselkumab was also associated with higher probability of achieving PASI 75 (87.8% vs 77.1% [OR, 2.14; 95% CI, 1.54-2.94]) and PASI 100 (49.7% vs 28.1% [OR, 2.53; 95% CI, 2.00-3.23]) compared with ustekinumab.
- 825 patients from the VOYAGE 1/2 trials and 853 patients from the NAVIGATE trial were included in the analysis.
- Funding: Janssen Inc.
- Indirect comparisons between trials with different settings may have introduced confounding factors and bias.